Subscribe
intellectual-property
Jirsak / shutterstock.com
18 August 2016Americas

Janssen Remicade patent invalidated in Massachusetts

The US District Court for the District of Massachusetts has issued a ruling on a summary judgment motion filed by Celltrion Healthcare and Hospira, invalidating a Janssen patent related to Remicade (infliximab).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pfizer to launch second-ever biosimilar in the US
18 October 2016   Pfizer announced yesterday that it will launch a biosimilar of one of Johnson & Johnson’s (J&J) best-selling drugs, Remicade (infliximab), which brought in a total of $9.2 billion in revenue last year.
Americas
Janssen drops biosimilar suit against Samsung
15 November 2017   Janssen, a subsidiary of Johnson & Johnson, has dropped a lawsuit against Samsung's biopharmaceutical arm Samsung Bioepis.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Pfizer to launch second-ever biosimilar in the US
18 October 2016   Pfizer announced yesterday that it will launch a biosimilar of one of Johnson & Johnson’s (J&J) best-selling drugs, Remicade (infliximab), which brought in a total of $9.2 billion in revenue last year.
Americas
Janssen drops biosimilar suit against Samsung
15 November 2017   Janssen, a subsidiary of Johnson & Johnson, has dropped a lawsuit against Samsung's biopharmaceutical arm Samsung Bioepis.

More on this story

Americas
Pfizer to launch second-ever biosimilar in the US
18 October 2016   Pfizer announced yesterday that it will launch a biosimilar of one of Johnson & Johnson’s (J&J) best-selling drugs, Remicade (infliximab), which brought in a total of $9.2 billion in revenue last year.
Americas
Janssen drops biosimilar suit against Samsung
15 November 2017   Janssen, a subsidiary of Johnson & Johnson, has dropped a lawsuit against Samsung's biopharmaceutical arm Samsung Bioepis.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool